Scientists at Rubedo Life Sciences have announced the first positive results of a new drug against skin ageing. This drug, RLS-1496, works by clearing senescent cells from the skin. These are damaged cells that no longer function properly and contribute to ageing processes. Until now, the research had largely not progressed beyond laboratory studies, but this drug has now been successfully tested on humans in an initial safety phase.
The medicine is applied via the skin, which carries fewer risks than pill-based medications. It targets skin problems such as plaque psoriasis and atopic dermatitis, conditions in which damaged cells play a major role. By passing the initial clinical trial phase, Rubedo Life Sciences demonstrates that the medicine is safe and can have an effective action on the skin.
Senolytics are a new class of medicines that target ageing cells. Removing these cells can slow down the ageing process and reduce age-related diseases. Much further research is needed in the coming years, but the first step proves that this treatment method is clinically feasible.
This development can be important for older people. It offers hope for better treatments against skin ageing and chronic skin conditions. The research also shows how new medicines can contribute specifically to healthy ageing by tackling ageing factors.
Source: Reason
